With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
Diversifying its portfolio to include late-phase antiviral agent
The investment in land is Rs. 19.85 crore
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Subscribe To Our Newsletter & Stay Updated
